KING OF PRUSSIA, Pa.— May 1, 2017—Genomind, a Montgomery County-based personalized medicine company bringing advancements to mental health care through genetic testing, has reached two achievements that are fueling its headquarters expansion.
First, the company announced its Genecept Assay® has been used to aid clinicians in treating a total of over 100,000 patients to date with mental health challenges. The test identifies patient-specific genetic markers that indicate which treatments are likely to work as intended, have no effect or cause adverse effects.
Second, Genomind recently unveiled additional enhancements to the Genecept Assay. With the enhanced test, the Genecept Assay now covers more than 20 drug classes, 122 medications approved by the U.S. Food and Drug Administration, 18 clinically validated genes and 97 percent of medications used to treat depression, anxiety, bipolar disorder, schizophrenia, attention deficit disorder and autism. It also offers comprehensive coverage of pain medications.
Genecept has been shown in peer-reviewed published studies to improve patient outcomes and reduce overall medical costs; further details are available at https://genomind.com/clinical-evidence/.
In order to meet its growing customer demand, Genomind has increased employment by one-third in the past year and has expanded its King of Prussia headquarters by 50 percent.
“The additional space will allow us to serve more clinicians and partners who are interested in Genomind’s services that are helping to optimize treatment decisions for patients coping with mental health issues,” said Michael Koffler, Genomind’s President and CEO. “Our expansion is a result of strong demand from our target market. We really see Montgomery County as a pivotal part of our success, as this area provides a great combination of talent and resources.”
Life Sciences Pennsylvania, which represents the entire life sciences industry in the Keystone State, recently named Genomind its Emerging Company of the Year.
In addition, Genomind has been recognized by Modern Healthcare as one of the best places to work and was included in The Philadelphia 100® for being among the 100 fastest-growing companies in the region.
Genomind is a personalized medicine company bringing innovation to mental health care through genetic testing. Genomind is comprised of pioneering researchers and thought leaders in psychiatry and neurology and specializes in pharmacogenetic laboratory testing for psychiatry. Genomind is committed to partnering with clinicians to improve their patients’ lives. Learn more at www.genomind.com.
About the Genecept Assay®
The Genecept Assay is a genetic test designed to help clinicians optimize treatment decisions for their patients with mental illness. It identifies patient-specific genetic markers that indicate which treatments are likely to work as intended, have no effect or cause adverse effects. It is an easily administered cheek swab test that analyzes key genes that have been selected based on hundreds of studies showing that variations in these genes can inform treatment decisions. The Assay is used to guide treatment for a range of psychiatric conditions, including depression, anxiety, obsessive-compulsive disorder (OCD), attention-deficit hyperactivity disorder (ADHD), bipolar disorder, post-traumatic stress disorder (PTSD), autism, schizophrenia, chronic pain and substance abuse, and has been shown in peer-reviewed published studies to improve patient outcomes and reduce overall medical costs. Each Assay provides clinicians with an easy-to-read patient report and a complimentary psychopharmacogenomic consultation. Learn more at www.genomind.com
Vice President, Marketing and Corporate Communications